UK Cell And Gene Therapy Manufacturing Market Size & Outlook
UK cell and gene therapy manufacturing market, 2018-2030 (US$M)
Related Markets
UK cell and gene therapy manufacturing market highlights
- The UK cell and gene therapy manufacturing market generated a revenue of USD 314.4 million in 2022 and is expected to reach USD 1,974.0 million by 2030.
- The UK market is expected to grow at a CAGR of 25.8% from 2023 to 2030.
- In terms of segment, cell therapy was the largest revenue generating therapy type in 2022.
- Gene Therapy is the most lucrative therapy type segment registering the fastest growth during the forecast period.
Cell and gene therapy manufacturing market data book summary
| Market revenue in 2022 | USD 314.4 million |
| Market revenue in 2030 | USD 1,974.0 million |
| Growth rate | 25.8% (CAGR from 2022 to 2030) |
| Largest segment | Cell therapy |
| Fastest growing segment | Gene Therapy |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Gene Therapy, Cell Therapy |
| Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
Other key industry trends
- In terms of revenue, UK accounted for 4.3% of the global cell and gene therapy manufacturing market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, France cell and gene therapy manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- France is the fastest growing regional market in Europe and is projected to reach USD 3,354.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell And Gene Therapy Manufacturing Market Scope
Cell And Gene Therapy Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK cell and gene therapy manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.
Cell therapy was the largest segment with a revenue share of 57.25% in 2022. Horizon Databook has segmented the UK cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
According to a 2019 survey conducted by the Cell and Gene Therapy Catapult, UK, there are 26 MIA and MHRA MIA (IMP) licensed gene and cell therapy manufacturing facilities in the UK. Moreover, there were only two licensed commercial production (MIA) facilities in the country as of November 2019.
This well-established facility network coupled with a strong workforce is anticipated to fuel market growth. This indicates that the country is providing a platform for continued market growth. In recent years, the country witnessed significant growth in the commercial sector.
According to a report published in July 2019 by the UK BioIndustry Association (BIA) and Alliance for Regenerative Medicine (ARM), cell and gene therapy companies in the UK received a total funding of USD 1006.28 million (£785m) (conversion rate: 1-pound sterling = 1.28 USD) in 2018, which was a 66% increase from 2017.
Reasons to subscribe to UK cell and gene therapy manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK cell and gene therapy manufacturing market databook
-
Our clientele includes a mix of cell and gene therapy manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK cell and gene therapy manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into UK cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
UK cell and gene therapy manufacturing market size, by therapy type, 2018-2030 (US$M)
UK Cell And Gene Therapy Manufacturing Market Outlook Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
